Adaptive Biotechnologies
ADPT • NASDAQ
Adaptive Biotechnologies is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Chad Robins, with a market cap of $1.9B.
CEOChad Robins
Next Earnings
Upcoming earnings announcement for Adaptive Biotechnologies
Date
Thursday, April 30, 2026 (in 3 weeks)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.16
Revenue Estimate
$61.3M
Earnings History
Past 12 earnings reports for Adaptive Biotechnologies
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 5, 2026 | Q4 2025 | -$0.09Est: -$0.19 | +52.6% | $71.7MEst: $60.9M | +17.7% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.15Est: -$0.15 | 0.0% | $60.2MEst: $66.0M | -8.8% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.17Est: -$0.24 | +29.2% | $58.9MEst: $49.5M | +18.9% | 10-Q |
| May 1, 2025 | Q1 2025 | -$0.20Est: -$0.31 | +35.5% | $52.4MEst: $42.1M | +24.4% | 10-Q |
| Feb 11, 2025 | Q4 2024 | -$0.23Est: -$0.24 | +4.2% | $47.5MEst: $46.1M | +3.1% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.22Est: -$0.29 | +24.1% | $46.4MEst: $40.2M | +15.5% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$0.31Est: -$0.33 | +6.1% | $43.2MEst: $38.7M | +11.7% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.33Est: -$0.34 | +2.9% | $41.9MEst: $38.8M | +8.0% | 10-Q |
| Feb 14, 2024 | Q4 2023 | -$0.30Est: -$0.30 | 0.0% | $45.8MEst: $48.5M | -5.5% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.35Est: -$0.34 | -2.9% | $37.9MEst: $43.0M | -11.7% | — |
| Aug 2, 2023 | Q2 2023 | -$0.33Est: -$0.33 | 0.0% | $48.9MEst: $45.5M | +7.6% | 10-Q |
| May 3, 2023 | Q1 2023 | -$0.40Est: -$0.38 | -5.3% | $37.6MEst: $36.8M | +2.3% | — |